[1]
|
A. Lyell, “Toxic Epidermal Necrolysis: An Eruption Resembling Scalding of the Skin,” British Journal of Dermatology, Vol. 68, No. 11, 1956, pp. 355-361.
doi:10.1111/j.1365-2133.1956.tb12766.x
|
[2]
|
S. A. Coopman, R. Johnson, R. Platt, et al., “Cutaneous Diseases and Drug Reactions in HIV Infection,” The New England Journal of Medicine, Vol. 328, No. 23, 1993, pp. 1670-1674.
|
[3]
|
A. Carr, C. Swanson, R. Penny, et al., “Clinical and Laboratory Markers of Hypersensitivity to TrimethoprimSulfamethoxazole in Patients with Pneumocystis Carinii Pneumonia and AIDS,” The Journal of Infectious Diseases, Vol. 167, No. 1, 1993, pp. 180-185.
doi:10.1093/infdis/167.1.180
|
[4]
|
A. Carr, B. Tindall and D. A. Cooper, “Patterns of Multiple Drug Hypersensitivity in HIV-Infected Patients,” AIDS, Vol. 7, No. 11, 1993, pp. 1532-1533.
doi:10.1097/00002030-199311000-00023
|
[5]
|
B. Milpied-Homsi, V. Relliquet, A. Huart, et al., “Skin Toxicity of Nevirapine Used as First-Line Treatment 100 Patients,” Annales de Dermatologie et de Venereologie, Vol. 126, 1999, p. 2S21.
|
[6]
|
D. Halvir, S. H. Cheeseman, M. McLaughlin, et al., “High-Dose Nevirapine: Safety, Pharmacokinetics and Antiretroviral Effect in Patients with HIV,” The Journal of Infectious Diseases, Vol. 171, No. 3, 1995, pp. 537-545. doi:10.1093/infdis/171.3.537
|
[7]
|
J. P. Fagot, M. Mockenhaupt, J. N. Bouwes-Bavinck, et al., “Nevirapine and the Risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis,” AIDS, Vol. 15, No. 14, 2001, pp. 1843-1848.
doi:10.1097/00002030-200109280-00014
|
[8]
|
R. T. d’Aquilla, M. D. Hughes, V. A. Jonhson, et al., “Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection,” Annals of Internal Medicine, Vol. 124, No. 12, 1996, pp. 1019-1030.
doi:10.7326/0003-4819-124-12-199606150-00001
|
[9]
|
A. Barner and M. Myers, “Nevirapine and Rashes,” Lancet, Vol. 351 , No. 9109, 1998, pp. 1133-1134.
doi:10.1016/S0140-6736(05)79417-4
|
[10]
|
B. Diatta, F. F. D. Ly, N. F. Ngom, C. T. Cissé, F. Fall, et al., “Toxidermia with Névirapine during Pregnancy about 3 Cases Report,” Annales de Dermatologie et de Venereologie, Vol. 138, No. C50, 2011, p. S54.
|
[11]
|
A. Shilad, M. Predanic, S. C. Perni, et al., “Human Immunodeficiency Virus, Pregnancy and Stevens-Johnson Syndrome,” Obstetrics & Gynecology, Vol. 105, No. 5, 2005, pp. 1254-1256.
doi:10.1097/01.AOG.0000157766.49494.99
|
[12]
|
I. C. Niemeijer, M. C. Van Praag and N. Van Gemund, “Relevance and Consequences of Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Gynecology,” Archives of Gynecology and Obstetrics, Vol. 280, No. 5, 2009, pp. 851-854.
doi:10.1007/s00404-009-1008-1
|
[13]
|
K. Kratzert, F. Marks, C. Antoine, et al., “Pregnancy Post Stevens-Johnson Syndrome: Case Report and Review of the Literature,” Obstetrics & Gynecology, Vol. 72, No. 3, 1988, pp. 447-450.
|
[14]
|
W. H. Chung, S. I. Hung, J. Y. Yang, et al., “Granulysin is a Key Mediator for Disseminated Keratinocyte Death in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis,” Nature Medicine, Vol. 14, No. 12, 2008, pp. 1343-1350. doi:10.1038/nm.1884
|
[15]
|
N. Claessens, L. Delbeke, J. Lambert, et al., “Toxic Epidermal Necrolysis Associated with Treatment for Preterm Labor,” Dermatology, Vol. 196, No. 4, 1998, pp. 461-462.
doi:10.1159/000017950
|
[16]
|
M. F. Struck, T. Liss, Y. Illert, et al., “Toxic Epidermal Necrolysis in Pregnancy: Case Report and Review of the Literature,” Journal of Burn Care & Research, Vol. 31, No. 5, 2010, pp. 816-821.
doi:10.1097/BCR.0b013e3181eed441
|
[17]
|
R. B. Pollard, P. Robinson and K. Dransfield, “Safety Profile of Nevirapine a Nonnucleosid Reverse Transcriptase Inhibitor for the Treatment of HIV,” Clinical Therapeutics, Vol. 20, No. 6, 1998, pp. 1071-1092.
doi:10.1016/S0149-2918(98)80105-7
|
[18]
|
H. Knobel, J. M. Miro, P. Domingo, et al., “Failure of Short-Term Prednisone Regimen to Prevent Nevirapine Associated Rash: Double-Blind Placebo-Controlled Trial, the GESIDA09/99 Study,” Journal of Acquired Immune Deficiency Syndromes, Vol. 28, No. 1, 2001, pp. 14-18.
|
[19]
|
A. Carr, S. Vella, MD. de Jong et al., “A Controlled Trial of Nevirapine Plus Zidovudine alone in p24 Antigenaemic HIV-Infected Patients. The Dutch-Italian-Australian Nevirapine Study Group,” AIDS, Vol. 10, No. 6, 1996, pp. 635-641. doi:10.1097/00002030-199606000-00009
|
[20]
|
J. S. Montaner, P. Reiss, D. A. Cooper, et al., “A Randomized, Double Blind Trial Comparing Combinaisons of Nevirapine, Didanosine and Zidovudine for Hivinfected Patients: The INCAS Trial,” JAMA, Vol. 279, No. 12, 1998, 930-937. doi:10.1001/jama.279.12.930
|
[21]
|
F. Lawson-Ayayi, R. Thiebaut, R. Ramanampamonjy, et al., “A Cohort of Nevirapine Tolerance in Clinical Practice: French Aquitaine Cohort 1997-1999,” Clinical Infectious Diseases, Vol. 35, No. 10, 2002, pp. 1231-1237.
doi:10.1086/343046
|
[22]
|
E. Caumes, P. Bossi, C. Katlama, et al., “Antiretroviral Drug Eruption to Patients Infected with HIV,” La Presse Médicale, Vol. 32, No. 28, 2003, pp. 1325-1333.
|
[23]
|
A. Rotunda, R. J. Hirsch, N. Scheinfeld, et al., “Severe Cutaneous Reactions Associated with the Use of Human Immunodeficiency Virus Medications,” Acta DermatoVenereologica, Vol. 83, No. 1, 2003, pp. 1-9.
doi:10.1080/00015550310002611
|
[24]
|
Y. Bourezane, D. Salard, B. Hoen, et al., “DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) Syndrome Associated with Nevirapine Therapy,” Clinical Infectious Diseases, Vol. 27, No. 5, 1998, pp. 1321-1322.
|
[25]
|
V. Kohlbrenner, K. Dansfield, V. Cotton, et al., “Cutaneous Eruptions Associated with Nevirapine Therapy in HIV-1 Infected Patients Individuals (Abstract MoB 12021),” 10th International Conference on AIDS, Vancouver, 7-12 July 1996, p. 607.
|
[26]
|
J. S. Montaner, P. Cahn, C. Zala, et al., “Randomized, Controlled Study of the Effects of Short Course of Prednisone on the Incidence of Rash Associated Nevirapine in Patients Infected with HIV-1,” Journal of Acquired Immune Deficiency Syndromes, Vol. 33, No. 1, 2003, pp. 41-46. doi:10.1097/00126334-200305010-00007
|
[27]
|
S. J. Bersoff-Matcha, W. C. Miller, J. A. Aberg, et al., “Sex Differences in Nevirapine Rash,” Clinical Infectious Diseases, Vol. 32, No. 1, 2001, pp. 124-129.
doi:10.1086/317536
|
[28]
|
P. Brocklehurst and R. French, “The Association between Maternal HIV Infection and Perinatal Outcome: A Systematic Review of the Literature and Meta-Analysis,” British Journal of Obstetrics and Gynaecology, Vol. 105, No. 8, 1998, pp. 836-848.
doi:10.1111/j.1471-0528.1998.tb10227.x
|
[29]
|
European Collaborative Study, “Swiss Mother and Child Cohort Study: Combination Antiretroviral Therapy and Duration of Pregnancy,” AIDS, Vol. 14, No. 18, 2000, pp. 2913-2920. doi:10.1097/00002030-200012220-00013
|
[30]
|
E. G. Szyld, E. M. Warley, L. Freimanis, et al., “Maternal Antiretroviral Drugs during Pregnancy and Infant Low Birth Weight and Preterm Birth,” AIDS, Vol. 20, No. 18, 2006, pp. 2345-2353.
doi:10.1097/01.aids.0000253362.01696.9d
|
[31]
|
A. M. Cotter, A. G. Garcia, M. L. Duthely, et al., “Is Antiretroviral Therapy during Pregnancy Associated with an Increased Risk of Preterm Delivery, Low Birth Weight, or Stillbirth?” The Journal of Infectious Diseases, Vol. 193, No. 9, 2006, 1195-1201. doi:10.1086/503045
|